Efficacy of 2 first-generation EGFR TKIs, gefitinib versus erlotinib, in patients with EGFR mutated advanced non-small cell lung cancer. Gefitinib Erlotinib EGFR mutation Non-small cell lung cancer
Conditions
Interventions
Patients with EGFR mutated advanced non-small cell lung cancer receiving gefitinib as first line treatment.,Patients with EGFR mutated advanced non-small cell lung cancer receiving erlotinib as first
Treatment,Treatment
gefitinib ,erlotinib
Sponsors
Chaoprayayommarat Hospital Research Ethical Committee
Eligibility
Sex/Gender
All
Age
15 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Age more than 15 years old 2.Histology or cytology confirmed diagnosis of non-small cell lung cancer stage 3B or 4. 3.Received first line treatment with gefitinib or erlotinib. 4.Have at least 1 time of radiologic assessment
Exclusion criteria
Exclusion criteria: Can not tolerated or denied receiving gefitinib or erlotinib until disease progression. Received surgery/Radiotherapy/chemotherapy during treatment with gefitinib or erlotinib.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free survival at the end of study Progression free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival at the end of study Overall survival | — |
Countries
Thailand
Contacts
Public ContactDheeravee Ratanapichayachai
Chaoprayayommarat Hospital
Outcome results
None listed